ArticleBMC neurology2025
Unveiling the role of PSD95 phosphorylation after traumatic brain injury: insights from phosphoproteomic analysis.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inorganic, Synthetic, Natural, and Innovative Hybrid Hydrogen Sulfide Donors and Inhibitors of Its Biosynthesis in the Treatment of Central and Peripheral Nervous System Injuries: A Systematic Analytical Review.International journal of molecular sciences · 2025Pooled it
- Post-Translational Modifications in Traumatic Brain Injury: Decoding the Proteomic Landscape and Molecular Mechanisms of Secondary Injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Stemness-associated MEF-derived extruded nanovesicles cooperate withNanoscale advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTraumatic brain injury (TBI) is a global public health problem. Pathophysiology of TBI remains unclear. Thus, methods of TBI treatment are limited. Phosphorylation plays a vital role in many neurological diseases, including TBI. As an emerging technique, phosphoproteomic has been widely applied in many fields.
methodsRats were subjected to controlled cortical impact (CCI) or divided to sham group. Protein was extracted from cortex, digested and labeled by iTRAQ. After undergoing mass spectrometry (MS), differential expressed phosphorylated sites (DEPSs) were identified, and proteins of these DEPSs were also listed. PSD95 was chosen as a target protein for further research. ZL006 was used to treat TBI rats. Nissl staining was applied to assess lesion volume, apoptosis was evaluated by TUNEL immunofluorescence staining, and PSD95 phosphorylation was further validated by Western blot.
resultsA total of 2753 phosphorylation sites across 1001 proteins were identified. A total of 221 DEPSs were identified. Phosphorylation of PSD95 at serine 417 and 418 were significantly upregulated after TBI. PSD95 had most interactions with other differential expressed phosphorylated proteins (DEPPs). Following ZL006 treatment, brain lesion volume and apoptotic rate were significantly reduced, and phosphorylation of PSD95 at Ser418 was decreased.
conclusionsAfter TBI, PSD95 was significantly phosphorylated at Ser417 and Ser418. ZL006 markedly reduced brain lesion volume and apoptotic rate and suppressed the phosphorylation of PSD95 at Ser418.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.